Canaccord analyst Kyle Mikson reiterates a Hold rating on Olink (OLK) with a $26 price target following last month’s Q3 report. The results were driven by solid kits revenue that was higher than estimated, which also resulted in a meaningful increase in kits gross margin quarter-over-quarter, the analyst tells investors in a research note. The firm views the pending takeover by Thermo Fisher (TMO) as a solid outcome for shareholders and does not believe another buyer will make an offer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on OLK:
- Canaccord does not expect another takeover bid for Olink
- Olink reports Q3 EPS (1c), consensus (8c)
- Olink reports third quarter 2023 financial results
- Novogene Asia Pacific Middle East and Africa adopts Olink® Explore HT technology to accelerate multi-omics research with next generation proteomics
- Olink price target raised to $26 from $18 at Morgan Stanley